Targeted immunotherapy against FSHR has achieved significant breakthroughs, including TCE, NKCE, and novel DNA vaccines, which can help in OC treatment and prevent tumor recurrence after the first-line treatment of FSHR+ tumors. This evidence concerns the gene FSHR and neoplasm.